Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide ...

As has been the case for the past few years, financing for small- and micro-cap biotech companies remains challenging. The ...

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company’s lead development ...

MTX240 is a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction ...

Closes Private Placement Financing of Up to $104.5 Million - Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe - Advances Proposed Expedited Regulatory ...

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Mayo Clinic researchers developed an experimental nanotherapy that delivers two cancer drugs directly to brain tumors, ...

Researchers at the University of Arizona have rewritten a basic assumption about one of the most studied growth pathways in biology. Their work, published in Nature Communications, shows that the ...

Focused on therapies for rare skin diseases, this clinical-stage biotech saw a notable director purchase coincide with a ...

BDRX READ THE FULL BDRX RESEARCH REPORT We are initiating coverage of Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) with a valuation of $7.00. Biodexa is a clinical-stage GI oncology company focused on ...